Acceptability and Efficacy of Pain Reprocessing Therapy in Racially/ Ethnically Diverse Adults With Chronic Back Pain

Sponsor
University of Colorado, Denver (Other)
Overall Status
Recruiting
CT.gov ID
NCT05820204
Collaborator
(none)
75
1
3
20.8
3.6

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to learn which treatment works better for adults with chronic pain. This study are comparing three treatments: Pain Reprocessing Therapy (PRT), Cognitive Behavioral Therapy (CBT), and usual care (whatever a person is already doing to cope with their pain).

The study's main questions are:
  • Does PRT work well for adults with chronic pain?

  • Which treatment works better for lowering pain: PRT, CBT, or usual care?

This study will compare PRT, CBT, and usual care to see which is most helpful for lowering pain and helping with other problems that people with chronic pain can have.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Pain reprocessing therapy (PRT)
  • Behavioral: Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)
  • Other: Usual care
N/A

Detailed Description

Investigators recently developed a novel psychological treatment, pain reprocessing therapy (PRT). Using a combination of cognitive, exposure-based, and somatic psychotherapy techniques, PRT aims to promote patients' reconceptualization of pain as due to reversible, non-dangerous brain activity rather than peripheral pathology. Critically, PRT aims to reduce or eliminate pain, rather than increasing functioning.

In the first trial of PRT (N = 151), 66% of patients randomized to PRT were pain-free or nearly so at post-treatment, as compared to fewer than 20% of placebo and usual care controls. This trial was conducted in a primarily White, highly-educated population with face-to-face treatment, and how PRT effects would generalize to a more diverse population or to telehealth treatment is not known.

PRT was developed to better address pain intensity and pain-related outcomes compared to leading psychological treatments for pain such as cognitive behavioral therapy (CBT). This study aims to yield preliminary findings on the comparative efficacy of PRT vs. CBT vs. usual care. Developing scalable effective, non-pharmacological chronic pain treatments and testing their efficacy in racial/ethnic minorities is an urgent societal need. Accordingly, this study also tests a remotely-delivered PRT intervention in a diverse patient population.

Aim 1 of this study is to test the feasibility (recruitment & retention) of conducting a randomized clinical trial comparing remotely-delivered PRT with an active comparator, CBT, and usual care and to assess the acceptability (helpfulness, satisfaction, & impact) of PRT in a diverse, lower socioeconomic status (SES) patient population.

Aim 2 of this study is to test the comparative efficacy of PRT vs. CBT and PRT vs. usual care on pain intensity and other pain-related outcomes.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Three-arm randomized control trialThree-arm randomized control trial
Masking:
Single (Outcomes Assessor)
Masking Description:
Outcome assessment will be completed via automated transmission of a redCAP link, and as such is inherently blinded. Fidelity assessment will be conducted by blinded fidelity assessors who are otherwise not involved in the study.
Primary Purpose:
Treatment
Official Title:
Feasibility and Acceptability of Pain Reprocessing Therapy in Racially/ Ethnically Diverse Adults With Chronic Back Pain
Anticipated Study Start Date :
Apr 10, 2023
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Jan 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Pain reprocessing therapy (PRT)

PRT has 5 components: 1) education about the origin of pain in the brain, its reversibility, and the pain-fear cycle; 2) reinforcing education using personal biography; 3) "somatic tracking" of pain through mindfulness and reappraisal of pain sensations as non-dangerous; 4) lowering the level of personal threat that may trigger pain sensation; and 5) inducing positive affect in periods of pain. Patients will attend 1 assessment and education telehealth session with a physician followed by 8, 50-minute, therapist-led sessions. Pacing will be flexible, ranging from 5-12 weeks, to increase accessibility. Treatment will be provided by experienced PRT clinicians. All PRT sessions will be remotely-delivered.

Behavioral: Pain reprocessing therapy (PRT)
A promising new psychotherapy for chronic pain

Active Comparator: Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)

CBT-CP, considered the leading psychological treatment for chronic pain, is a structured, time-limited intervention that aims to teach patients how to better manage chronic pain and improve their quality of life. Participants will receive 9, 50-minute sessions of CBT-CP over 5 - 12 weeks. The VA CBT-CP protocol contains an initial orientation involving education and familiarization with the CBT-CP approach to chronic pain. The protocol then includes sessions that focus on topics such as exercise, relaxation, pleasant activities, cognitive coping, and sleep. All CBT-CP sessions will be remotely-delivered.

Behavioral: Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)
A psychotherapy for chronic pain that has 30+ years of research support.
Other Names:
  • Cognitive Behavioral Therapy
  • Active Comparator: Usual Care

    Participants will be asked to continue whatever they are already doing to care for their back pain. Length of the usual care condition will be 5 weeks, the expected mean completion time of the PRT and CBT arms, and may be adjusted at mid-enrollment to match treatment arm length more closely.

    Other: Usual care
    Participants will be asked to continue to do whatever they are currently doing to manager their pain
    Other Names:
  • Treatment as usual
  • Outcome Measures

    Primary Outcome Measures

    1. Pain intensity [Primary time point is the day after post-treatment, 1.5 months on average]

      Last-week average pain intensity is assessed via the Brief Pain Inventory Short Form (BPI-SF). The BPI-SF assess pain severity and its impact on functioning. It consists of 9 total items including 4 pain items and 5 pain interference items. The 4 pain items measure pain in the last week on a numerical rating scale of 0 (no pain at all) to 10 (pain as bad as you can imagine).

    2. Session Attendance [This value will be calculated a day after post-treatment for the last participant, approximately 1 year from the start of enrollment]

      Session attendance is a feasibility measure calculated as the proportion or percentage of people randomized to either PRT or CBT who attended at least 6 sessions.

    Secondary Outcome Measures

    1. Pain interference [Primary time point is the day after post-treatment, 1.5 months on average]

      Pain interference is assessed via the pain interference items (5-items) of the Brief Pain Inventory Short Form (BPI-SF). The BPI-SF assess pain severity and its impact on functioning. It consists of 9 total items including 4 pain items and 5 pain interference items. The 5 pain interference items measure pain interference in the last week on a numerical rating scale of 0 (does not interfere) to 10 (completely interferes).

    2. Depression [Primary time point is the day after post-treatment, 1.5 months on average]

      Depression is assessed via the 8-item depression sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF). The PROMIS scale as a whole monitors the physical, mental, and social health of adults and children. Each item in the PROMIS-SF depression sub-scale is rated on a 5-point scale of 1 (never) to 5 (always).

    3. Positive Affect [Primary time point is the day after post-treatment, 1.5 months on average]

      Assessed via the PANAS is a self-report questionnaire that consists of two 10-item scales to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much).

    4. Anxiety [Primary time point is the day after post-treatment, 1.5 months on average]

      Anxiety is assessed via the 8-item anxiety sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF). The PROMIS scale as a whole monitors the physical, mental, and social health of adults and children. Each item in the PROMIS-SF anxiety sub-scale is rated on a 5-point scale of 1 (never) to 5 (always).

    5. Anger [Primary time point is the day after post-treatment, 1.5 months on average]

      Anger is assessed via the 5-item anger sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF). The PROMIS scale as a whole monitors the physical, mental, and social health of adults and children. Each item in the PROMIS-SF anger sub-scale is rated on a 5-point scale of 1 (never) to 5 (always).

    6. Sleep quality [Primary time point is the day after post-treatment, 1.5 months on average]

      Sleep quality is assessed via the 8-item sleep disturbance sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF). The PROMIS scale as a whole monitors the physical, mental, and social health of adults and children. 7 of the 8 items in the PROMIS-SF sleep disturbance sub-scale are rated on a 5-point scale of 1 (not at all) to 5 (very much) while 1 item is rated on a 5-point scale of 1 (very poor) to 5 (very good).

    7. Client satisfaction [Primary time point is the day after post-treatment, 1.5 months on average]

      Client Satisfaction is assessed the Patients' Global Impression of Change (PGIC). The PGIC is a single-item self-report scale that measures a patient's belief about the efficacy of treatment. The single-item is rated on a 7-point scale of 1 (No change or condition has got worse) to 7 (a great deal better).

    8. Physical Activity Levels [Primary time point is the day after post-treatment, 1.5 months on average]

      Physical activity levels are assessed via the 7-item, self-reported International Physical Activity Questionnaire - Short Form (IPAQ-SF). The IPAQ-SF measures sitting times as well as physical activity and their intensities as performed by a participant during the last 7 days. Types of physical activities and their intensities are recorded in time (Hours per day: minutes per day)

    9. Medication Use [Primary time point is the day after post-treatment, 1.5 months on average]

      Medication use is assessed by asking participants to provide the names, dosages, and frequencies of the medications that they are currently taking for pain management only.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Last-week average back pain of at least 4 of 10 at the two pretreatment timepoints (online pre-screening and informed consent session)

    • Back pain that is an ongoing problem for at least half the days of the last 6 months

    • Back pain that is worse than leg pain.

    Exclusion Criteria:
    • Current litigation or compensation associated with pain or plans to apply for compensation or engage in litigation in the next 6 months

    • Active suicidal ideation with intent, recent history of suicide attempt, or recent history of suicide attempts or self-harm behaviors within the past 5 years (including non-suicidal self-harm)

    • Recent history of inpatient psychiatric hospitalization within the past 5 years

    • Active, current psychosis or mania

    • Active, current substance abuse, or problems with substance abuse within the past 2 years

    • Instability in living conditions or major interfering life events:

    • Major surgery or other major medical event planned in coming six months

    • Unsure whether will reliably have suitable conditions for telehealth appointments over the next two months, including a computer or tablet, reliable fast internet, and a quiet comfortable room that is reliably available.

    • Major, interfering changes in employment or housing anticipated over the next six months

    • Failure to complete at least 85% (6 of 7) of EMA surveys in the first week of the study (post-consent, pre-randomization)

    • Leg pain worse than back pain

    • Back surgery within the last 2 years

    • Difficulty controlling bladder function (to screen out cauda equina syndrome)

    • Serious medical illness (e.g., current, or recent cancer diagnosis, severe cardiovascular disease)

    • Recent large unexplained, unintended weight loss (20lbs or more)

    • Recent vertebral fracture/ known spinal fractures or tumors

    • Known sensory/motor abnormalities in the trunk or legs.

    • Self-reported diagnosis of a specific inflammatory disorder: rheumatoid arthritis, polymyalgia rheumatica, scleroderma, Lupus, or polymyositis

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Colorado Anschutz Medical Campus Aurora Colorado United States 80045

    Sponsors and Collaborators

    • University of Colorado, Denver

    Investigators

    • Principal Investigator: Jonathan K. Ashar, Ph.D., University of Colorado - Anschutz Medical Campus

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Colorado, Denver
    ClinicalTrials.gov Identifier:
    NCT05820204
    Other Study ID Numbers:
    • 22-2162
    First Posted:
    Apr 19, 2023
    Last Update Posted:
    Apr 19, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Colorado, Denver
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 19, 2023